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Numerous synergistic cancer immunotherapy com-
binations have been identified, but the effects of rela-
tive dose timing are rarely considered. In established
syngeneic mouse tumor models, we found that stag-
gering interferon-a (IFNa) administration after, rather
than before or simultaneously with, serum-persis-
tent interleukin-2 (IL-2) and tumor-specific antibody
significantly increased long-termsurvival. Successful
combination therapy required IFNa-induced activa-
tion of cross-presenting CD8a+ dendritic cells (DCs)
following the release of antigenic tumor debris by
the IL-2- and antibody-mediated immune response.
Due to decreased phagocytic ability post-matura-
tion, DCs activated too early captured less antigen
and could not effectively prime CD8+ T cells. Tempo-
rally programmingDCactivation tooccur after tumor-
icidal activity enhanced tumor control by multiple
distinct combination immunotherapies, highlighting
dose schedule as an underappreciated factor that
can profoundly affect the success of multi-compo-
nent immunotherapies.
INTRODUCTION
Immunotherapy possesses unprecedented potential for cancer
treatment, promoting antitumor host immune responses that
can generate durable remissions. Many studies have demon-
strated synergistic tumor control using various immunotherapies
in combination with one another or with chemotherapy or radio-
therapy (Melero et al., 2015). With major efforts focused on
identifying treatment combinations that affect non-redundant
immune pathways for maximal antitumor activity, less thoughtCell Repo
This is an open access article under the CC BY-Nis given to the order in which therapeutic components are admin-
istered. Often treatments are provided either concurrently for
convenience or sequentially as patients are transitioned to a
more promising drug; very rarely are concurrent and sequential
combinations compared directly (Chen and Mellman, 2013;
Melero et al., 2015). Moreover, the few studies documenting
schedule-dependent synergy in combination therapies do not
elucidate the mechanism underlying such synergy (Park et al.,
2010; Reck et al., 2013; Schwartz et al., 1982), making it difficult
to determine whether optimal dose timing can be rationally
devised for drugs with known mechanisms of action.
To investigate the effect of dose schedule on antitumor effi-
cacy in combination immunotherapy, we combined a well-char-
acterized extended half-life interleukin-2 and tumor-specific
antibody regimen (FcIL2 + TA99; Zhu et al., 2015) with inter-
feron-a (IFNa), the only other FDA-approved cytokine for cancer
treatment, in syngeneic solid tumor models. Since IL-2 and IFNa
signal through distinct pathways, their synergistic potential has
been assayed extensively, though clinical trials have failed to
show a survival benefit from combination therapy over mono-
therapy (Cohen and Kaufman, 2007). However, since we had
found serum-persistent FcIL2 to be more potent than IL-2 in
delaying tumor progression together with TA99 (Zhu et al.,
2015), we hypothesized that this regimen’s ability to mediate
innate and adaptive immunity-dependent tumor cytotoxicity
could be well complemented by IFNa’s pleiotropic effects.
Endogenous or administered type I IFNs, such as IFNa, are
respectively required for or enhance the antitumor activity
of many cancer immunotherapies, including monoclonal anti-
bodies and peptide vaccines (Sikora et al., 2009; Stagg et al.,
2011), and they are also necessary for spontaneous tumor
rejection (Diamond et al., 2011; Fuertes et al., 2011).
We demonstrate here that FcIL2 + TA99 exhibits unexpectedly
strong schedule-dependent antitumor synergy with IFNa, such
that delaying IFNa injection with respect to FcIL2 + TA99 admin-
istration results in profoundly improved survival compared torts 17, 2503–2511, December 6, 2016 ª 2016 The Author(s). 2503
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
simultaneous administration of all three components or injection
of IFNa prior to FcIL2 + TA99. Furthermore, we find that the rela-
tive timing of IFNa-mediated CD8a+ dendritic cell (DC) activation
ultimately determines the outcome of IFNa combination immu-
notherapy. We also show that the chronology of DC activation
by various other combination immunotherapies significantly im-
pacts antitumor responses, highlighting dose schedule as a
crucial variable to consider when combining multiple immuno-
modulatory agents.
RESULTS
IFNa Exhibits Potent Schedule-Dependent Antitumor
Synergy with Serum-Persistent IL-2 and Tumor-Specific
Antibody
To testwhether the relative timingof combination immunotherapy
component administrationaffects antitumor efficacy,weused the
poorly immunogenic B16F10 melanoma model, allowing subcu-
taneous tumors to establish in syngeneic C57BL/6 mice prior to
treatment.Micewere treatedwithFcIL2 +TA99,which comprises
an extended serum half-life IL-2 and an antitumor murine IgG2a
antibody against TRP1 (Zhu et al., 2015).Murine IFNawasadmin-
istered either 24 hr before, concurrently with, or 48–96 hr after
FcIL2 + TA99 (Figure S1A). While injecting IFNa prior to or simul-
taneously with FcIL2 + TA99 did not induce durable remissions,
staggering IFNa administration 48 hr after FcIL2 + TA99 treatment
resulted in cure rates ranging from 67% to 100% (Figures 1A, 1B,
and S1B). All three immunotherapeutic agents were required for
the long-term survival benefit conferred by staggered IFNa com-
bination therapy, since omission of any agent significantly dimin-
ishedantitumor efficacy (Figures1BandS1C). Althoughsynergis-
tic tumor control depended greatly on the relative timing of IFNa
and FcIL2 + TA99 administration, treatment outcomes were rela-
tively unaffected by IFNa dosage (Figure S1D).
CD8+ T Cells, CD8a+ DCs, and IFNg Are Required for
Effective IFNa Combination Immunotherapy
We next sought to identify a mechanistic basis for the schedule-
dependent antitumor synergy observed between IFNa and
FcIL2 + TA99. IFNa can directly inhibit tumor cell proliferation,
and indeed it demonstrated mild antiproliferative activity when
incubated with several cancer cell lines (Figure S1E). However,
if inhibition of tumor cell proliferation were IFNa’s major contribu-
tion, then earlier IFNa administration would be expected to result
in better outcomes. Moreover, even cultured in the presence of
an IFNa concentration 2-fold greater than peak serum levels
following a therapeutic dose, B16F10 cells exhibited only an
65% reduction in proliferation compared to untreated controls
(Figure S1E). These data imply that IFNa’s antiproliferative
effects play a minor role in tumor control mediated by the com-
bination immunotherapy.
IFNa also can stimulate tumoricidal functions in a variety of
immune effector cells. After immunotherapy, intratumoral levels
of the chemokines IP-10, MIP-2, MIG, andMCP-1 were elevated
(Figure S2A), likely contributing to the local recruitment of natural
killer (NK) cells, T cells, neutrophils, and phagocytes (Figures
S2D, S2E, and S3A). Strikingly, mice depleted of CD8+ T cells
or macrophages, but not other immune effector cells, failed to2504 Cell Reports 17, 2503–2511, December 6, 2016respond to staggered IFNa combination therapy (Figures 1C,
S2B, and S2C). While IFNg-neutralizing antibodies significantly
impaired the antitumor activity of the combination therapy,
TNF-neutralizing antibodies did not (Figures 1C and S2C). Other
studies have further identified a necessary role for type I IFNs in
mediating antitumor cytotoxic T cell responses through the pro-
motion of tumor antigen cross-presentation by the CD8a+ DC
subset (Diamond et al., 2011; Fuertes et al., 2011). We found
that the efficacy of the staggered IFNa combination therapy
was severely attenuated in Batf3/mice lacking this DC subset
(Figures 1D and S2F), revealing an additional requirement for
CD8a+ DCs in therapy-induced tumor rejection.
Although the extent of tumor infiltration by immune effector
cells appeared similar for both simultaneous and staggered
IFNa combination therapies (Figures S2D, S2E, and S3A), the
two treatment regimens exhibited marked differences in the
timing of immune cell activation. Expression of the maturation
marker CD86 by draining lymph node CD8a+ DCs closely trailed
the time of IFNadosing (Figure 1E), consistent with IFNa’s known
ability to activate DCs (Luft et al., 1998). Since the CD8a+ DC
subset is heavily involved in priming lymph node T cells that
then traffic to the tumor (Diamond et al., 2011), after treatment
we monitored the percentages of CD8+ T cells in both compart-
ments that expressed the activation markers CD69 and CD25.
Interestingly, in the lymph node, CD69 and CD25 expression
peaked 2 days following IFNa administration. Expression of
both markers quickly decreased thereafter (Figure 1F), reflecting
transient induction in the case of CD69 and migration of acti-
vated T cells to the tumor in the case of CD25 (Fuertes et al.,
2013). In the tumor, CD8+ T cells also strongly upregulated acti-
vation marker expression soon after IFNa dosing. The close
correlation of IFNa dose timing with tumor-proximal CD8a+ DC
and CD8+ T cell activation suggests that coordinating DC matu-
ration with antigen uptake is a critical requirement for efficacy.
Antitumor Responses to IFNa Combination
Immunotherapy Depend on the Timing of CD8a+ DC
Activation
Upon activation and maturation, DCs not only upregulate a vari-
ety of costimulatory molecules but also lose phagocytic capac-
ity, relinquishing the ability to capture new antigens in favor of an
increased ability to cross-prime CD8+ T cells specific for already
internalized antigens (Wilson et al., 2006). We therefore hypoth-
esized that the timing of DC activation relative to the release of
immunogenic tumor antigens was a key determinant of thera-
peutic efficacy in this IFNa combination therapy. Previously,
we showed that antitumor innate immunity, as characterized
by granulocyte respiratory burst activity and inflammatory cyto-
kine release, peaks 2 days after FcIL2 + TA99 administration
(Zhu et al., 2015). If CD8a+ DCs became activated and poorly en-
docytic before the treatment-mediated immune response gener-
ated substantial antigenic tumor debris, then their ability to prime
CD8+ T cells would be hampered due to an insufficiency of inter-
nalized tumor antigens available for cross-presentation.
To test this hypothesis, we administered IFNa both simulta-
neously with FcIL2 + TA99 therapy and again afterward. Despite
the total IFNa dose being the same, administration of a portion of
that dose concurrently with antibody had a dominant-negative
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Figure 1. Relative Timing of Combination Immunotherapy Component Administration Determines Synergistic Antitumor Efficacy and
Requires Specific Elements of Innate and Adaptive Immunity
(A) Survival curves for mice injected subcutaneously (s.c.) with 106 B16F10 melanoma cells, then treated on days 6 and 12 with PBS or FcIL2 + TA99. Mice given
FcIL2 + TA99 also received IFNa at the indicated time points after FcIL2 + TA99 treatment (n = 5–9 per group).
(B) Survival curves for mice treated as described in (A), or with one of the three therapeutic components omitted, are shown (n = 5–13 per group).
(C) Survival curves for mice treated as described in (A). Mice given immunotherapy also were injected with the indicated antibodies (n = 8–15 per group).
(D) Survival curves for wild-type or Batf3/ mice treated as described in (A) are shown (n = 5–10 per group).
(E) CD86 expression by B16F10 tumor-draining lymph node CD8a+ DCs (CD3CD11chiPDCA-1CD8a+) from immunotherapy-treatedmice is shown (n = 4–5 per
group).
(F) Percentages of draining lymph node or intratumoral CD8+ T cells expressing CD69 or CD25. Cells were isolated from immunotherapy-treated B16F10-bearing
mice (n = 4–5 per group).
Data represent mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 between the indicated pairs or versus the corresponding color group in the
legend). See also Figures S1 and S2.effect, resulting in significantly worse tumor control than giving
IFNa only after FcIL2 + TA99 (Figures 2A, S3C, and S1D), pre-
sumably because IFNa-matured DCs became less phagocytic
following the first IFNa dose. Furthermore, although CD8a+
DCs can play an essential role as producers of IL-12 and IL-15(Ferlazzo et al., 2004), intratumorally injected IL-12 or IL-15 com-
plex was unable to rescue the antitumor efficacy of staggered
IFNa combination therapy in Batf3/mice (Figure S3B), consis-
tent with the hypothesis that the cross-priming ability of CD8a+
DCs is the dominant contributor to tumor control in this context.Cell Reports 17, 2503–2511, December 6, 2016 2505
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B Figure 2. Properly Timed CD8a+ DC Activa-
tion Is Necessary for Optimal CD8+ T Cell
Priming in Combination Immunotherapy
(A) Survival curves for mice injected s.c. with 106
B16F10 melanoma cells, treated on days 6 and 12
with PBS or FcIL2 + TA99 and IFNa as indicated,
are shown (n = 5–10 per group).
(B) Percentages of GFP+ draining lymph node
CD8a+ DCs frommice treated as in (A), except with
B16F10-GFP tumors, are shown (n = 5–10 per
group).
(C) IFNg expression by peripheral blood CD8+
T cells. On day 12, blood was collected from
immunotherapy-treated wild-type or Batf3/mice
bearing established s.c. B16F10 tumors and incu-
bated for 6 hr in the presence of brefeldin A
and monensin, with PMA/ionomycin restimulation.
Background IFNg expression levels without PMA/
ionomycin were subtracted (n = 10–12 per group).
(D) Percentages of peripheral blood CD8+ T cells
staining positive for H-2Kb/SIINFEKL tetramer.
Mice were immunized s.c. with OVA and treated
with IFNa either 24 hr before or after immunization.
Blood was collected 7 days later (n = 10 per group).
Data represent mean ± SEM (ns, not significant;
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001
between the indicated pairs or versus the
corresponding color group in the legend). See
also Figure S3.To more directly evaluate DC phagocytic ability following
immunotherapy, we treated mice bearing B16F10 tumors that
stably expressed EGFP, and we used GFP signal as a proxy
for tumor antigen uptake by draining lymph node CD8a+ DCs
(Figure 2B). A few days later, greater percentages of GFP+
CD8a+ and GFP+CD86+ CD8a+ DCs were encountered in mice
treated with staggered IFNa combination therapy than in those
treated with simultaneous or simultaneous + staggered IFNa
combination therapies (Figures 2B and S3D).
To examine whether increased tumor antigen uptake by
CD8a+ DCs corresponds to better CD8+ T cell priming, we eval-
uated CD8+ T cell function by analyzing IFNg production in
response to ex vivo restimulation. A significantly greater fraction2506 Cell Reports 17, 2503–2511, December 6, 2016of circulating CD8+ T cells expressed IFNg
after staggered versus simultaneous IFNa
combination therapy, and CD8+ T cells
from mice treated with the staggered
IFNa combination generated more IFNg
per cell than those from mice treated
with the simultaneous IFNa combination
(Figure 2C). Intriguingly, administering
the staggered IFNa combination therapy
in Batf3/ mice diminished the magni-
tude, but not the frequency, of IFNg pro-
duction by CD8+ T cells (Figure 2C), sug-
gesting that CD8a+ DCs contribute to
therapeutic efficacy by amplifying the level
of IFNg production per CD8+ T cell rather
than by simply increasing the percentage
of IFNg-producing cells. Staggering IFNaadministration also boosted expression of the degranulation
marker CD107a by intratumoral CD8+ T cells compared to
administering IFNa simultaneously with FcIL2 + TA99, although
the fractions of IFNg-producing CD8+ T cells were similar in
both groups of mice at the analyzed time point (Figure S3E).
Finally, to assess the effect of CD8a+ DC maturation timing on
the priming of antigen-specific CD8+ T cells, we quantified the
generation of ovalbumin (OVA)-specific T cells following subcu-
taneous OVA immunization in animals exposed to IFNa at
different times. Whereas mice treated with IFNa after OVA injec-
tion showed a robust anti-OVA CD8+ T cell response, OVA-
specific T cells were not detected in mice pre-exposed to IFNa
(Figure 2D), again indicating that DC activation prior to antigen
AC D
B Figure 3. Effective Combination Immuno-
therapy Elicits Protective Antitumor Immune
Memory
(A) Survival curves for mice treated with FcIL2 +
TA99 and IFNa +48 hr, rechallenged on day 100
with 105 B16F10 cells s.c. Naive mice challenged
with 105 B16F10 s.c. also were monitored as a
control (n = 12–19 per group).
(B) Percentages of peripheral blood CD8+ T cells
expressing IFNg following B16F10 tumor re-
challenge. On day 8 post-rechallenge, blood was
collected from mice treated as described in (A) and
incubated for 6 hr in the presence of brefeldin A and
monensin, with PMA/ionomycin restimulation.
Background IFNg expression levels detected using
controls incubated without PMA/ionomycin were
subtracted (n = 3–10 per group).
(C) ELISPOT analysis of B16F10-specific IFNg
production by splenocytes isolated from mice
treated as described in (A) on day 6 post-re-
challenge. Splenocytes (106) and 2.5 3 104 irradi-
ated tumor cells were co-incubated for 24 hr.
Nonspecific responses were quantified by co-in-
cubation with the TC-1 tumor cell line. Background
IFNg expression levels detected using splenocytes
incubated in the absence of tumor cells were sub-
tracted (n = 3–7 per group).
(D) Endogenous antitumor antibody response
following B16F10 tumor rechallenge as measured by immunoblot. At 3–5 weeks post-rechallenge, sera were obtained from mice treated as described in (A) and
analyzed for antibodies reactive against B16F10 cell lysate. A control immunoblot using TA99 antibody against B16F10 cell lysate also was performed. Each lane
represents pooled sera from three mice (naive) or serum from one individual mouse (FcIL2 + TA99, IFNa 48 hr).
Data represent mean ± SEM (*p < 0.05, **p < 0.01, and ****p < 0.0001 between the indicated pairs or versus the corresponding color group in the legend). See also
Figure S4.exposure can significantly obstruct the generation of an effective
T cell response against that antigen. Together, these data accen-
tuate the importance of delaying CD8a+ DC activation until an
innate immune response has generated sufficient tumor anti-
genic debris for maximal tumor antigen endocytosis and cyto-
toxic T cell priming by this DC subset to occur.
Effective IFNa Combination Immunotherapy Protects
against Subsequent Tumor Rechallenge
To determine whether mice treated with staggered IFNa combi-
nation therapy that survived B16F10 tumor challenge could
reject subsequent challenge without additional treatment, we re-
challenged surviving animals with B16F10 tumor cells at a distal
site. More than two-thirds of these previously treated mice re-
jected the secondary challenge, whereas all of the control naive
animals exhibited rapid tumor outgrowth (Figures 3A and S4A).
Furthermore, circulating CD8+ T cells from rechallenged, previ-
ously treated mice showed greater functional ability than those
from naive mice challenged with the same tumor inoculum (Fig-
ure 3B). The cellular response to rechallenge was tumor specific,
since a higher frequency of IFNg secretion was detected by
enzyme-linked immune spot (ELISPOT) upon the incubation of
splenocytes from previously treated mice with B16F10 mela-
noma cells versus unrelated TC-1 lung cancer cells (Figure 3C).
Additionally, immunoblots using sera from rechallenged, previ-
ously treated mice to probe B16F10 cell lysates revealed the
presence of antitumor antibodies to multiple epitopes beyond
the TRP1 protein targeted by TA99 (Figures 3D and S4B). Collec-tively, these findings confirm that staggered IFNa combination
therapy elicits long-term protective cellular and humoral anti-
tumor immunity.
Temporally Programmed Dose Schedule Effects Are
Generalizable to Other DC-Activating Immunotherapies
Many immunomodulators induce DC maturation, motivating
us to investigate whether other DC-activating agents exhibit
schedule-dependent synergies. We combined FcIL2 + TA99
with the synthetic a-galactosylceramide analog KRN7000, the
agonistic anti-CD40 antibody 3/23, the nucleic acid analog
poly(I:C), or the lipopolysaccharide derivative MPLA, which acti-
vate DCs indirectly via invariant NKT cell-based transactivation
or directly through costimulatory or Toll-like receptors (Fujii
et al., 2003; Hennessy et al., 2010; White et al., 2011). Strikingly,
tumor-bearing mice treated with KRN7000, 3/23, poly(I:C), or
MPLA after FcIL2 + TA99 therapy showed dramatically improved
survival versus those treated with these DC activators prior to
FcIL2 + TA99 (Figures 4A–4D and S5A–S5D). Despite the vastly
different biophysical properties and DC-activating mechanisms
of the tested immunostimulatory agents, temporally program-
ming DC activation to occur predominantly following antigen-
generating tumoricidal activity led to more effective combination
therapy in every case, emphasizing that component dosing or-
der can strongly govern the efficacy of combination therapies.
For further generalization, we tested our combination immuno-
therapies in two alternate syngeneic tumor models, adminis-
tering IFNa with FcIL2 + 7.16.4, an anti-Her2 murine IgG2aCell Reports 17, 2503–2511, December 6, 2016 2507
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Figure 4. Schedule-Dependent Synergy Is Generalizable to a Wide Range of Combination Immunotherapies in Various Tumor Models
(A–D) Survival curves for mice injected s.c. with 106 B16F10 melanoma cells, then treated on days 6 and 12 with PBS or FcIL2 + TA99. Mice given FcIL2 + TA99
also received KRN7000 (A), 3/23 (B), poly(I:C) (C), or MPLA (D) at the indicated times (n = 13–15 per group).
(E) Survival curves for mice injected s.c. with 106 DD-Her2/neu breast cancer cells, then treated on days 6 and 12 with PBS or FcIL2 + 7.16.4. Mice given FcIL2 +
7.16.4 also received IFNa at the indicated times (n = 5–10 per group).
(F) Survival curves for mice injected s.c. with 2.53 104 RM9 prostate cancer cells, then treated on days 6 and 12 with PBS or FcIL2 + 3F8. Mice given FcIL2 + 3F8
also received IFNa at the indicated times (n = 12–13 per group).
(G) Survival curves for mice injected s.c. with 106 B16F10 melanoma cells, then treated on days 6 and 12 with intraperitoneal (i.p.) PBS or cyclophosphamide.
Mice given cyclophosphamide also received IFNa at the indicated times (n = 5 per group).
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 versus the corresponding color group in the legend. See also Figure S5.antibody, to BALB/c mice bearing established DD-Her2/neu
breast tumors (Draganov et al., 2015) or with FcIL2 + 3F8, an
anti-GD2murine IgG3 antibody, to C57BL/6 mice bearing estab-
lished RM9 prostate tumors (Zhu et al., 2015). Staggering IFNa
treatment after FcIL2 + antitumor antibody provided superior tu-
mor control than giving all three components simultaneously
(Figures 4E, 4F, S5E, and S5F). Lastly, we used the chemother-
apeutic agent cyclophosphamide, which can induce immuno-
genic tumor cell death (Bezu et al., 2015), in lieu of FcIL2 +
TA99 to generate tumor debris in the B16F10 model. IFNa2508 Cell Reports 17, 2503–2511, December 6, 2016given staggered after cyclophosphamide prolonged survival
compared to simultaneous administration of chemotherapy
and IFNa (Figures 4G and S5G), again most likely due to
CD8a+ DC activation after, rather than concurrent with, tumorici-
dal activity (Figure S5G). Thus, the enhanced antitumor efficacy
conferred by properly timed DC activation also was validated for
combination therapies with an alternate means of tumor cell
killing and in two additional tumor models using different mouse
strains, demonstrating the broad applicability of this temporal
programming approach.
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As cancer immunotherapy comes of age, much attention has
focused on determining which drug classes exhibit synergistic
antitumor activity (Chen and Mellman, 2013; Melero et al.,
2015), while comparatively little effort has been directed toward
considering the importance of dose schedules for these
combinations. Here we show that the relative timing of drug
administration can play a pivotal role in dictating combination
immunotherapy outcomes, using an aggressive syngeneic
tumor model to characterize the mechanism by which such
schedule-dependent antitumor synergy arises. Before treat-
ment, the paucity of tumor-derived antigens in the immunosup-
pressive tumor microenvironment and draining lymph node
results in poor CD8+ T cell priming by immature CD8a+ DCs.
Administration of a tumoricidal regimen, such as a tumor-spe-
cific antibody with IL-2 support, induces extensive tumor cell
death (Zhu et al., 2015), generating tumor debris for capture
and cross-presentation by the DCs, provided they receive a
maturation signal only after tumor-derived antigens become
available (Figure 5). Thus, in the subcutaneous B16F10 tumor
model, a 2-day delay in DC-activating IFNa administration
following the injection of tumoricidal therapy yields an 85%
survival rate, in stark contrast to 0% long-term survivors when
both therapies are given simultaneously.We further demonstrate
with a variety of other combination therapies and tumor models
that superior tumor control is achieved by temporally program-
ming DC activation to occur after the culmination of tumoricidal
activity, highlighting a general strategy for enhancing the thera-
peutic efficacy of many existing treatment combinations.
Our unexpected finding that premature pharmacological
CD8a+ DC maturation impedes the generation of a durable
antitumor immune response nevertheless agrees with a prior
observation that the systemic activation of CD8a+ DCs by ma-
laria infection or microbial ligands greatly impaired subsequent
cross-presentation and resulted in immunosuppression (Wilson
et al., 2006). By contrast, we show that, when triggered at an
appropriate time, DC activation significantly improves the effi-
cacy of cancer immunotherapy (Figures 1A and 2A). ActivatedCD8a+ DCs primed a robust CD8+ T cell response against tu-
mor-derived antigens, leading to durable remissions and rejec-
tion of subsequent tumor challenge (Figure 3A). Although these
CD8+ T cells exhibited specific reactivity to irradiated B16F10 tu-
mor cells (Figure 3C), we did not detect T cells reactive to known
B16F10 peptide epitopes, including gp100, TRP1, TRP2, and
p15E (Overwijk and Restifo, 2001; data not shown). More sensi-
tive techniques, such as cancer exome analysis or tandem mini-
gene library screening, might be needed to identify the precise
antigen specificities of the CD8+ T cells mediating tumor regres-
sion in this study (Lu et al., 2014; Matsushita et al., 2012).
The near-total ablation of combination immunotherapy effi-
cacy in mice deficient in CD8+ or Batf3-dependent cells (Figures
1C and 1D), along with published evidence that endogenous
antitumor cytotoxic T cell responses selectively require type I
IFN signaling in CD8a+ DCs (Diamond et al., 2011; Fuertes
et al., 2011), prompted us to focus our investigation on the
CD8a+ DC subset, which is considered to have the most potent
CD8+ T cell cross-priming ability (den Haan and Bevan, 2002). It
nonetheless is likely that alternate mechanisms also contribute
to the schedule-dependent synergy observed in our combina-
tion immunotherapy, since IFNa can activate other DC subsets,
including Batf3-independent CD8a DCs (Diamond et al., 2011).
Indeed, type I IFN signaling was shown to inhibit phagocytic
capacity in CD8a DCs, hindering Th1-dependent responses
to malaria (Haque et al., 2014). In addition, wild-type mice
treated with simultaneous IFNa combination therapy demon-
strated weaker CD8+ T cell priming than Batf3/ mice treated
with staggered IFNa combination therapy (Figure 2C), indicating
a deleterious effect of untimely IFNa exposure on Batf3-
independent antitumor immunity. These data suggest that
premature activation of CD8a DCs, which can cross-present
to CD8+ T cells under certain circumstances (den Haan and
Bevan, 2002), could partially account for the decreased survival
when DC maturation occurs concurrently with instead of after
tumoricidal activity. Further work is necessary to definitively
characterize the effects of IFNa dose timing on CD8a DC
numbers, activation status, and relationship to effective anti-
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Our work indicates that a strategy of administering tumoricidal
therapy prior to activating DCs for enhanced antitumor synergy
generalizes to combinations involving a wide spectrum of cyto-
toxic or DC-stimulating treatments, and it reveals several areas
for further exploration. First, the ability of tumor-specific antibody
to mediate tumor cell opsonization by DCs may contribute to
treatment efficacy, since combinationswith antibody hadgreater
efficacy than those without; antibody isotype also may influence
tumor control (Figure 4). Second, recent studies have linked the
success of several anticancer therapies, including STAT3 inhibi-
tors and stimulator of IFN gene (STING) agonists, with the potent
induction of type I IFN signaling leading to tumor regression (Cor-
rales et al., 2015; Yang et al., 2015), making these therapies
promising candidates for synergistic DC activation in combina-
tion with tumoricidal agents. Last, the principle of temporal pro-
gramming may extend to other steps in the generation of an anti-
tumor immune response, including T cell activation, infiltration
into tumors, and recognition of cancer cells (Chen and Mellman,
2013). For example, previous findings that injection of plasmid
IL-2-immunoglobulin after, but not concurrently with, anHIV vac-
cine boosted immune responses (Barouch et al., 1998) and that
pre-exposure to IL-2 impaired subsequent antigen-specific
CD4+ T cell activation (Sckisel et al., 2015) suggest that adminis-
tering T cell stimulants, such as IL-2, only after antigen presenta-
tion and costimulation have occurred may recapitulate the
temporal progression of endogenous immune responses and
further augment the efficacy of combination cancer therapies.
In conclusion, we have uncovered a simple yet powerful
approach to improve the efficacy of combination cancer immu-
notherapies, and we have characterized the biological mecha-
nism underpinning this approach. Although studies to date
have focused on identifying drug classes that act synergistically,
we show that, when designing combination therapies, careful
attention should be paid not only to the nature of constituent
drugs but also to the relative timing of drug administration, as
premature immune stimulation may paradoxically suppress
rather than enhance antitumor activity. As our understanding of
cancer biology increases, the concept of temporally program-
ming immunological events to maximize the strength of an im-
mune response will enable the optimized combinatorial usage
of currently available immunomodulators, including immune
checkpoint inhibitors, agonistic and antitumor antibodies, cyto-
kines, and cancer vaccines.
EXPERIMENTAL PROCEDURES
More detailed procedures are provided in the Supplemental Experimental
Procedures.
Mice
C57BL/6 (Taconic or the Jackson Laboratory), BALB/c (Taconic), andBatf3/
(B6.129S(C)-Batf3tm1Kmm/J; bred in house from breeding pairs obtained from
the Jackson Laboratory) mice were maintained under specific pathogen-free
conditions and used at 6–10 weeks of age. All experiments were approved
by the MIT Division of Comparative Medicine and performed in accordance
with federal, state, and local regulations.
Tumor Treatment
For tumor induction, 106 B16F10 melanoma cells in 100 mL PBS were injected
subcutaneously into the flanks of C57BL/6 orBatf3/mice.Micewere treated2510 Cell Reports 17, 2503–2511, December 6, 2016retroorbitally on days 6 and 12 after tumor inoculation with 25 mg FcIL2 and/or
100 mg TA99. Some mice also received IFNa before, concurrent with, and/or
staggered after FcIL2 and/or TA99. Tumor length and width were measured
using calipers, and mice were euthanized when tumors reached 200 mm2.
Additional details, modifications, and models are described in the Supple-
mental Experimental Procedures.
Flow Cytometry
B16F10 tumors were induced as detailed above and treated with a single dose
of combination therapy prior to the preparation, staining, and analysis of single-
cell suspensions, as described in the Supplemental Experimental Procedures.
Statistical Analysis
Results were analyzed using GraphPad Prism 6 software with comparisons
performed as detailed in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.11.020.
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